BD (Becton, Dickinson and Company) announced it has completed the acquisition of TVA Medical, a company that develops minimally invasive vascular access solutions for patients with chronic kidney disease requiring haemodialysis including the everlinQ endoAVF System.
The addition of TVA Medical enables BD to offer the everlinQ endoAVF System, a new endovascular arteriovenous (AV) fistula creation technology that adds to the company’s end-stage renal disease portfolio of dialysis catheters, drug-coated balloons, standard angioplasty balloons and endovascular stent graft products. This technology will further improve BD’s ability to serve physicians and their patients by providing a minimally invasive option for creating critical AV fistulas for hemodialysis procedures.
“The addition of TVA Medical allows BD to provide another innovative device to physicians who treat patients suffering from chronic kidney disease requiring haemodialysis,” said Steve Williamson, worldwide president of Peripheral Intervention at BD. “This technology is highly complementary to our Peripheral Intervention offerings, and we will continue to bring new technologies to market that improve our category-leading ESRD portfolio. This is a great example of our continued strategy to use tuck-in acquisitions to advance category leadership.”
EverlinQ endoAVF System to become WavelinQ EndoAVF System
On 22 June, the US FDA announced De Novo marketing authorisation for the everlinQ endoAVF System. The system uses two, thin, flexible, magnetic catheters that are inserted into the ulnar artery and the ulnar vein in the arm through a small puncture. When placed close to each other, the magnets in each catheter attract, pulling the vessels together. After confirming alignment, an electrode from the venous catheter delivers radiofrequency energy to create the connection between the artery and vein. Embolization of the brachial vein is then recommended. The fistula is confirmed with an angiogram (X-ray image of the vascular system) to show that arterial blood is flowing to the low-pressure venous system. The procedure minimises the amount of vessel and skin trauma compared to traditional fistula creation using open surgery. The everlinQ endoAVF System enables an additional AV fistula location for patients than what is typically done surgically. The device is already commercially available in Europe and Canada. The product name will be transitioned to WavelinQ EndoAVF System during integration.
This transaction is not expected to have a material impact on BD results for fiscal 2018 or 2019. Future results for TVA Medical will be reported under the Peripheral Intervention business within the Interventional Segment at BD. The company used cash on hand to finance the transaction. This transaction does not impact the company’s previously-communicated commitment to deleverage as part of the Bard acquisition. Terms of the transaction were not disclosed.
